Anti-Apolipoprotein A II/ApoA-II antibody [EPR2913] - BSA and Azide free (Capture)

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Apolipoprotein A-II (also known as ApoA-II or Apolipoprotein A2) is a pivotal protein component of high-density lipoproteins (HDL) in the plasma. It is encoded by the APOA2 gene in humans and displays a molecular mass of approximately 17.4 kDa. Apolipoprotein A-II is primarily expressed in the liver and secreted into the bloodstream where it plays a direct role in lipid metabolism. Its structural composition includes a highly amphipathic α-helical structure that facilitates interaction with lipids aiding in lipoprotein formation and stability.

Biological function summary

Apolipoprotein A-II serves as a significant regulator of HDL metabolism and lipid transport. It is an integral part of HDL particles contributing to their stability and function. Apolipoprotein A-II influences lecithin-cholesterol acyltransferase (LCAT) activity which affects cholesterol esterification. Although less studied than its counterpart Apolipoprotein A-I ApoA-II's interaction with lipids and proteins such as CETP (cholesteryl ester transfer protein) suggests its involvement in lipid exchange and reverse cholesterol transport processes.

Pathways

Apolipoprotein A-II impacts the reverse cholesterol transport pathway and lipid metabolic processes. ApoA-II works closely with its relative Apolipoprotein A-I both part of the same HDL complex. Together they play essential roles in maintaining cholesterol homeostasis and promoting cholesterol efflux from cells back to the liver. The mechanism by which it modulates the function of lipoprotein lipase and hepatic lipase further implicates its role in lipid metabolism and energy balance processes.

Associated diseases and disorders

Dysfunction or abnormal levels of Apolipoprotein A-II have associations with cardiovascular diseases and metabolic syndromes. Altered ApoA-II levels correlate with an increased risk of atherosclerosis as its imbalance can drive perturbations in HDL composition and function. Moreover research links Apolipoprotein A-II with insulin resistance linking it with ApoA-I imbalanced lipid transport and metabolism in obesity and diabetes contexts. Understanding these connections may guide therapeutic strategies targeting ApoA-II to mitigate the risks and progression of these disorders.